Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.EDSA · Entity 7223 | Director | February 28, 2022 | March 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date February 28, 2022 · Filed March 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.71 · Expires 2032-02-28 | Direct | 11,000 |
Reported balance
After 2022-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-28 · Grant · Acquired 11,000 · Balance 11,000 F1: This option vests monthly in equal proportions over 12 months beginning on the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests monthly in equal proportions over 12 months beginning on the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2022 Filed Mar 8, 2022 00:56 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001654954-22-002660 · section16.xml · derivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2032-02-28 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the Grant Date. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 20:57 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001654954-21-004630 · section16.xml · derivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2031-04-22 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the Grant Date. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:39 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | OtherCommon Share Warrants (Right to Buy) · Derivative | 1,218 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001654954-20-012096 · section16.xml · derivative · entry 2 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,218 shares Expires 2020-11-08 Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:39 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | OtherCommon Shares | 1,218 | $4.00 | $4,872.00 |
DisclosureSEC source: 0001654954-20-012096 · section16.xml · nonDerivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,654 Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 19:57 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.44 | $0.00 |
DisclosureSEC source: 0001654954-20-011149 · section16.xml · derivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common shares · 20,000 shares Expires 2030-10-13 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the Grant Date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 11,389 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001654954-20-001649 · section16.xml · derivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Shares · 11,389 shares Expires 2030-02-12 F1 · derivative.exercise_date: 33% vested on 2/12/2020, with a prorata amount of the balance vesting monthly thereafter over the next 36 months until fully vested Read SEC document |
| January 08, 2020 Filed Jan 11, 2020 02:34 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share Warrants (Right to Buy) · Derivative | 1,218 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001654954-20-000308 · section16.xml · derivative · entry 3 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,218 Underlying: Common Shares · 1,218 shares Expires 2020-11-08 F3 · security: Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020. F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| January 08, 2020 Filed Jan 11, 2020 02:34 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share Warrants (Right to Buy) · Derivative | 1,827 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001654954-20-000308 · section16.xml · derivative · entry 2 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,827 Underlying: Common Shares · 1,827 shares Expires 2023-07-08 F2 · security: Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023. F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| January 08, 2020 Filed Jan 11, 2020 02:34 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 2,436 | $4.11 | $10,011.96 |
DisclosureSEC source: 0001654954-20-000308 · section16.xml · nonDerivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,436 F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 22:03 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 1,820 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001778480-19-000003 · primary_doc.xml · derivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,399 Underlying: Common Shares · 1,820 shares Expires 2027-09-26 F4 · derivative.exercise_price: In Canadian currency. F1 · shares: Represents additional options to purchase common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the "Issuer") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. ("Edesa") and the shareholders of Edesa. The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders. F2 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F3 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on September 26, 2018, and monthly thereafter through September 26, 2020. This option was issued in replacement of an option to purchase shares of Edesa. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 23:07 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 30,579 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001778480-19-000002 · primary_doc.xml · derivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,579 Underlying: Common Shares · 30,579 shares Expires 2027-09-26 F4 · derivative.exercise_price: In Canadian currency. F1 · shares: On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. F2 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F3 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on 9/26/18, and monthly thereafter through 9/26/20. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.